FindTrial
Sign In

Valproic acid and lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2026-525733-24-00
Enrollment
15
Registered
2026-08-11
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent and/or Metastatic Adenoid Cystic Carcinom

Brief summary

Change in quality of life according to EORTC QoL Q30 – HN43/ EORTC QLQ-C30, Overall response rate assessed according to RECIST 1.1

Interventions

DRUGLENVATINIB
DRUGSODIUM VALPROATE

Sponsors

Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Change in quality of life according to EORTC QoL Q30 – HN43/ EORTC QLQ-C30, Overall response rate assessed according to RECIST 1.1—

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 12, 2026